Search

Your search keyword '"Zhao, Fang‐Hui"' showing total 402 results
Start Over Author "Zhao, Fang‐Hui"
402 results on '"Zhao, Fang‐Hui"'

3. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

Author

Zhao, Fang-Hui, Wu, Ting, Hu, Yue-Mei, Wei, Li-Hui, Li, Ming-Qiang, Huang, Wei-Jin, Chen, Wen, Huang, Shou-Jie, Pan, Qin-Jing, Zhang, Xun, Hong, Ying, Zhao, Chao, Li, Qing, Chu, Kai, Jiang, Yun-Fei, Li, Ming-Zhu, Tang, Jie, Li, Cai-Hong, Guo, Dong-Ping, Ke, Li-Dong, Wu, Xin, Yao, Xing-Mei, Nie, Jian-Hui, Lin, Bi-Zhen, Zhao, Yu-Qian, Guo, Meng, Zhao, Jun, Zheng, Feng-Zhu, Xu, Xiao-Qian, Su, Ying-Ying, Zhang, Qiu-Fen, Sun, Guang, Zhu, Feng-Cai, Li, Shao-Wei, Li, Yi-Min, Pan, Hui-Rong, Zhang, Jun, Qiao, You-Lin, and Xia, Ning-Shao

Published
2022
Full Text
View/download PDF

8. Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening

Author

MMB, MMB Medische Staf, Infection & Immunity, Arbyn, Marc, Cuschieri, Kate, Bonde, Jesper, Schuurman, Rob, Cocuzza, Clementina, Broeck, Davy Vanden, Zhao, Fang Hui, Rezhake, Remila, Gultekin, Murat, de Sanjosé, Silvia, Canfell, Karen, Hawkes, David, Saville, Marion, Hillemanns, Peter, Dillner, Joakim, Berkhof, Johannes, Prétet, Jean Luc, Gheit, Tarik, Clifford, Gary, Basu, Partha, Almonte, Maribel, Wentzensen, Nicolas, Poljak, Mario, MMB, MMB Medische Staf, Infection & Immunity, Arbyn, Marc, Cuschieri, Kate, Bonde, Jesper, Schuurman, Rob, Cocuzza, Clementina, Broeck, Davy Vanden, Zhao, Fang Hui, Rezhake, Remila, Gultekin, Murat, de Sanjosé, Silvia, Canfell, Karen, Hawkes, David, Saville, Marion, Hillemanns, Peter, Dillner, Joakim, Berkhof, Johannes, Prétet, Jean Luc, Gheit, Tarik, Clifford, Gary, Basu, Partha, Almonte, Maribel, Wentzensen, Nicolas, and Poljak, Mario

Published
2024

9. Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening

Author

Arbyn, M, Cuschieri, K, Bonde, J, Schuurman, R, Cocuzza, C, Broeck, D, Zhao, F, Rezhake, R, Gultekin, M, de Sanjosé, S, Canfell, K, Hawkes, D, Saville, M, Hillemanns, P, Dillner, J, Berkhof, J, Prétet, J, Gheit, T, Clifford, G, Basu, P, Almonte, M, Wentzensen, N, Poljak, M, Arbyn, Marc, Cuschieri, Kate, Bonde, Jesper, Schuurman, Rob, Cocuzza, Clementina, Broeck, Davy Vanden, Zhao, Fang‐Hui, Rezhake, Remila, Gultekin, Murat, de Sanjosé, Silvia, Canfell, Karen, Hawkes, David, Saville, Marion, Hillemanns, Peter, Dillner, Joakim, Berkhof, Johannes, Prétet, Jean‐Luc, Gheit, Tarik, Clifford, Gary, Basu, Partha, Almonte, Maribel, Wentzensen, Nicolas, Poljak, Mario, Arbyn, M, Cuschieri, K, Bonde, J, Schuurman, R, Cocuzza, C, Broeck, D, Zhao, F, Rezhake, R, Gultekin, M, de Sanjosé, S, Canfell, K, Hawkes, D, Saville, M, Hillemanns, P, Dillner, J, Berkhof, J, Prétet, J, Gheit, T, Clifford, G, Basu, P, Almonte, M, Wentzensen, N, Poljak, M, Arbyn, Marc, Cuschieri, Kate, Bonde, Jesper, Schuurman, Rob, Cocuzza, Clementina, Broeck, Davy Vanden, Zhao, Fang‐Hui, Rezhake, Remila, Gultekin, Murat, de Sanjosé, Silvia, Canfell, Karen, Hawkes, David, Saville, Marion, Hillemanns, Peter, Dillner, Joakim, Berkhof, Johannes, Prétet, Jean‐Luc, Gheit, Tarik, Clifford, Gary, Basu, Partha, Almonte, Maribel, Wentzensen, Nicolas, and Poljak, Mario

Abstract

While HC2 and GP5+/6+ PCR-EIA were pivotal in test validation of new HPV assays, they represent the first generation of comparator tests based upon technologies that are not in widespread use anymore. In the current guideline, criteria for second-generation comparator tests are presented that include more detailed resolution of HPV genotypes. Second-generation comparator tests should preferentially target only the 12 genotypes classified as carcinogenic (IARC-group I), and show consistent non-inferior sensitivity for CIN2+ and CIN3+ and specificity for ≤CIN1 compared to one of the first-generations comparators, in at least three validation studies using benchmarks of 0.95 for relative sensitivity and 0.98 for relative specificity. Validation should take into account used storage media and other sample handling procedures. Meta-analyses were conducted to identify the assays that fulfill these stringent criteria. Four tests fulfilled the new criteria: (1) RealTime High-Risk HPV Test (Abbott), (2) Cobas-4800 HPV test (Roche Molecular System), (3) Onclarity HPV Assay (BD Diagnostics), and (4) Anyplex II HPV HR Detection (Seegene), each evaluated in three to six studies. Whereas the four assays target 14 carcinogenic genotypes, the first two identify separately HPV16 and 18, the third assay identifies five types separately and the fourth identifies all the types separately.

Published
2024

10. Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening.

Author

Arbyn, Marc, Cuschieri, Kate, Bonde, Jesper, Schuurman, Rob, Cocuzza, Clementina, Broeck, Davy Vanden, Zhao, Fang‐Hui, Rezhake, Remila, Gultekin, Murat, de Sanjosé, Silvia, Canfell, Karen, Hawkes, David, Saville, Marion, Hillemanns, Peter, Dillner, Joakim, Berkhof, Johannes, Prétet, Jean‐Luc, Gheit, Tarik, Clifford, Gary, and Basu, Partha

Subjects
EARLY detection of cancer, HUMAN papillomavirus, SAMPLING (Process), CERVICAL cancer, COMPARATOR circuits
Abstract

While HC2 and GP5+/6+ PCR‐EIA were pivotal in test validation of new HPV assays, they represent the first generation of comparator tests based upon technologies that are not in widespread use anymore. In the current guideline, criteria for second‐generation comparator tests are presented that include more detailed resolution of HPV genotypes. Second‐generation comparator tests should preferentially target only the 12 genotypes classified as carcinogenic (IARC‐group I), and show consistent non‐inferior sensitivity for CIN2+ and CIN3+ and specificity for ≤CIN1 compared to one of the first‐generations comparators, in at least three validation studies using benchmarks of 0.95 for relative sensitivity and 0.98 for relative specificity. Validation should take into account used storage media and other sample handling procedures. Meta‐analyses were conducted to identify the assays that fulfill these stringent criteria. Four tests fulfilled the new criteria: (1) RealTime High‐Risk HPV Test (Abbott), (2) Cobas‐4800 HPV test (Roche Molecular System), (3) Onclarity HPV Assay (BD Diagnostics), and (4) Anyplex II HPV HR Detection (Seegene), each evaluated in three to six studies. Whereas the four assays target 14 carcinogenic genotypes, the first two identify separately HPV16 and 18, the third assay identifies five types separately and the fourth identifies all the types separately. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Efficacy and immunogenicity of AS04‐HPV‐16/18 vaccine in females with existing cervical HR‐HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.

Author

Wen, Tian‐Meng, Xu, Xiao‐Qian, Zhao, Xue‐Lian, Pan, Cheng‐Hao, Feng, Yu‐Shu, You, Ting‐Ting, Gao, Meng, Hu, Shang‐Ying, and Zhao, Fang‐Hui

Abstract

Females with existing high‐risk HPV (HR‐HPV) infections remain at risk of subsequent multiple or recurrent infections, on which benefit from HPV vaccines was under‐reported. We pooled individual‐level data from four large‐scale, RCTs of AS04‐HPV‐16/18 vaccine to evaluate efficacy and immunogenicity in females DNA‐positive to any HR‐HPV types at first vaccination. Females receiving the AS04‐HPV‐16/18 vaccine in the original RCTs constituted the vaccine group in the present study, while those unvaccinated served as the control group. Vaccine efficacy (VE) against new infections and associated cervical intraepithelial neoplasia (CIN) 2+ in females DNA‐negative to the considered HR‐HPV type but positive to any other HR‐HPV types, VE against reinfections in females DNA‐positive to the considered HR‐HPV type but cleared naturally during later follow‐up, and levels of anti‐HPV‐16/18 IgG were assessed. Our final analyses included 5137 females (vaccine group = 2532, control group = 2605). The median follow‐up time was 47.88 months (IQR: 45.72‐50.04). For the prevention of precancerous lesions related to the non‐infected HR‐HPV types at baseline, VE against HPV‐16/18 related CIN 2+ was 82.70% (95% CI: 63.70‐93.00%). For the prevention of reinfections related to the infected HR‐HPV types following natural clearance, VE against HPV‐16/18 12MPI was non‐significant (p >.05), albeit robust immunity persisted for at least 48 months. Females with existing HR‐HPV infections at first vaccination still benefit from vaccination in preventing precancers related to the non‐infected types at baseline. VE against reinfections related to the infected types following natural clearance remains to be further investigated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Supplementary Tables 1 - 2 from An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China

Author

Zhao, Fang-Hui, primary, Jeronimo, Jose, primary, Qiao, You-Lin, primary, Schweizer, Johannes, primary, Chen, Wen, primary, Valdez, Melissa, primary, Lu, Peter, primary, Zhang, Xun, primary, Kang, Le-Ni, primary, Bansil, Pooja, primary, Paul, Proma, primary, Mahoney, Charles, primary, Berard-Bergery, Marthe, primary, Bai, Ping, primary, Peck, Roger, primary, Li, Jing, primary, Chen, Feng, primary, Stoler, Mark H., primary, and Castle, Philip E., primary

Published
2023
Full Text
View/download PDF

22. Data from An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China

Author

Zhao, Fang-Hui, primary, Jeronimo, Jose, primary, Qiao, You-Lin, primary, Schweizer, Johannes, primary, Chen, Wen, primary, Valdez, Melissa, primary, Lu, Peter, primary, Zhang, Xun, primary, Kang, Le-Ni, primary, Bansil, Pooja, primary, Paul, Proma, primary, Mahoney, Charles, primary, Berard-Bergery, Marthe, primary, Bai, Ping, primary, Peck, Roger, primary, Li, Jing, primary, Chen, Feng, primary, Stoler, Mark H., primary, and Castle, Philip E., primary

Published
2023
Full Text
View/download PDF

28. Additional file 1 of Cost-effectiveness of the screen-and-treat strategies using HPV test linked to thermal ablation for cervical cancer prevention in China: a modeling study

Author

Zhao, Xue-Lian, Zhao, Shuang, Xia, Chang-Fa, Hu, Shang-Ying, Duan, Xian-Zhi, Liu, Zhi-Hua, Wang, Yue-Yun, You, Ting-Ting, Gao, Meng, Qiao, You-Lin, Basu, Partha, and Zhao, Fang-Hui

Abstract

Additional file 1: Supplementary Materials. Fig. S1. Model structure. Fig. S2. Model outputs from the 1000 Monte Carlo simulations. Fig. S3a. Process of screening strategy with self-HPV without triage. Fig. S3b. Process of screening strategy with self-HPV16/18 triage. Fig. S3c. Process of screening strategy with self-HPV7 types triage. Fig. S3d. Process of screening strategy with physician-HPV without triage. Fig. S3e. Process of screening strategy with physician-HPV16/18 triage. Fig. S3f. Process of screening strategy with physician-HPV7 types triage. Fig. S3g. Process of screening strategy with physician-HPV with genotype triage. Fig. S3h. Process of screening strategy with physician-HPV with cytology triage. Fig. S4. Follow-up of women after treatment. Fig. S5a. Tornado diagram analysis for self-HPV without triage versus current physician-HPV with cytology strategy in urban area. Fig. S5b. Tornado diagram analysis for self-HPV without triage versus current physician-HPV with cytology strategy in rural area. Table S1. Natural history and transition probabilities parameters of cervical cancer. Table S2a. Cervical cancer screening costs for self-HPV without triage strategy. Table S2b. Cervical cancer screening costs for self-HPV16/18 triage strategy. Table S2c. Cervical cancer screening costs for self-HPV7 types triage strategy. Table S2d. Cervical cancer screening costs for physician-HPV without triage strategy. Table S2e. Cervical cancer screening costs for physician-HPV16/18 triage strategy. Table S2f. Cervical cancer screening costs for physician-HPV7 types triage strategy. Table S2g. Cervical cancer screening costs for physician-HPV with genotype triage strategy. Table S2h. Cervical cancer screening costs for physician-HPV with cytology triage strategy. Table S3. Disease status at follow-up based on combined endpoints. Table S4. Utility of women before and after thermal ablation or LEEP treatment. Table S5a. Lifetime costs, effectiveness, and incremental cost-effectiveness for all screen-and-treat strategies versus the currently used strategies (Undiscounted). Table S5b. Lifetime costs, effectiveness, and incremental cost-effectiveness for all screen-and-treat strategies versus the currently used strategies (Discounted, 3%).

Published
2023
Full Text
View/download PDF

34. Implementation of visual inspection with acetic acid and Lugol's iodine for cervical cancer screening in rural China

Author

Hu, Shang‐Ying, primary, Zhao, Xue‐Lian, additional, Zhao, Fang‐Hui, additional, Wei, Li‐Hui, additional, Zhou, Qi, additional, Niyazi, Mayinuer, additional, Liu, Ji‐Hong, additional, Wang, Chun‐Yan, additional, Li, Long‐Yu, additional, Cheng, Xiao‐Dong, additional, Duan, Xian‐Zhi, additional, Sauvaget, Catherine, additional, Qiao, You‐Lin, additional, and Sankaranarayanan, Rengaswamy, additional

Published
2022
Full Text
View/download PDF

35. The impact of low‐dose CT on smoking behavior among non‐smokers, former‐smokers, and smokers: A population‐based screening cohort in rural China

Author

Su, Zheng, primary, Li, Xuebing, additional, Wu, Heng, additional, Meng, Zhaowei, additional, Li, Yang, additional, Pan, Hongli, additional, Liang, Hao, additional, Wang, Ying, additional, Zhao, Fang‐Hui, additional, Qiao, Youlin, additional, Zhou, Qinghua, additional, and Fan, Ya‐Guang, additional

Published
2022
Full Text
View/download PDF

38. Clinical characteristics of 68 children with atypical hand, foot, and mouth disease caused by coxsackievirus A6: a single-center retrospective analysis

Author

Fang-Fang Cheng, Bing-Bing Zhang, Meng-Lu Cao, Qian Zhang, Qing-Hui Chen, Zhao-Fang Hui, Jian-Mei Tian, and Wen-Hua Yan

Subjects
Pediatrics, Perinatology and Child Health
Abstract

Hand, foot, and mouth disease (HFMD) caused by coxsackievirus A6 (CV-A6) has become prevalent in many parts of the world. It is commonly referred to as atypical HFMD which more likely to present as bullous lesions. Compared with traditional HFMD, its misdiagnosis rate is relatively high, which brings difficulties to clinical diagnosis. We retrospectively analyze the clinical characteristics of children with HFMD with bullous lesions caused by CV-A6.The study included 68 children with atypical HFMD caused by CV-A6 who were hospitalized from 2018 to 2020. Data of the children including age, sex, month of HFMD onset, the morphologies and distribution of rashes, the details of fever, the presence or absence of onychomadesis, and laboratory test results were analyzed and compared between an infant group (1 year), a toddler group (1-3 years), and a preschool group (3-6 years).Of the 68 children, 67 were younger than 5 years old, with a male to female ratio of 1.62:1. The disease peaked in the period from June to September. With 75.0% of the infant group had more than three kinds of rashes; 95.0% of the preschool group had rashes in more than five locations. These differences were statistically significant (P0.05). All children had fever. The peak fever in the toddler group was lower (P=0.033). No critical cases were observed in any of the groups. Of the 61 children who were successfully followed up, 68.9% developed onychomadesis within 2-3 weeks. The proportion of cases with abnormal liver function was 83.3%, 41.7%, and 10.0% in the infant, toddler, and preschool groups (P0.001). The proportion of cases with increased serum creatine kinase MB isoenzyme (CK-MB) were significantly higher in the toddler group (P0.05).Atypical HFMD caused by CV-A6 infection usually occurred in children under 5 years old. The morphologies of the rashes in the infant group changed more, while the rashes in the preschool group was more widely distributed. The incidence of critical cases was low. More than half of the cases can develop onychomadesis in the recovery period. Organ damage was relatively mild in the preschool group.

Published
2022

39. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China

Author

Zhao, Fang-Hui, Tiggelaar, Sarah M., Hu, Shang-Ying, Xu, Li-Na, Hong, Ying, Niyazi, Mayinuer, Gao, Xiao-Hong, Ju, Li-Rong, Zhang, Li-Qin, Feng, Xiang-Xian, Duan, Xian-Zhi, Song, Xiu-Ling, Wang, Jing, Yang, Yun, Li, Chang-Qing, Liu, Jia-Hua, Liu, Ji-Hong, Lu, Yu-Bo, Li, Li, Zhou, Qi, Liu, Jin-feng, Zhao, Na, Schmidt, Johannes E., and Qiao, You-Lin

Published
2012
Full Text
View/download PDF

48. The impact of low‐dose CT on smoking behavior among non‐smokers, former‐smokers, and smokers: A population‐based screening cohort in rural China.

Author

Su, Zheng, Li, Xuebing, Wu, Heng, Meng, Zhaowei, Li, Yang, Pan, Hongli, Liang, Hao, Wang, Ying, Zhao, Fang‐Hui, Qiao, Youlin, Zhou, Qinghua, and Fan, Ya‐Guang

Subjects
SMOKING, SMOKING cessation, NON-smokers, TEMPERANCE, EARLY detection of cancer
Abstract

Background: Lung cancer screening may provide a "teachable moment" for the smoking cessation and relapse prevention. However, the impact of lung cancer screening on smoking initiation in non‐smokers has not been reported. Methods: A baseline smoking behavior survey was conducted in 2000 participants who were screened by low‐dose computed tomography (LDCT) from 2014 to 2018. All participants were re‐surveyed on their smoking behavior in 2019. Of these, 312 participants were excluded, leaving 1688 participants in the final analysis. The smoking initiation rate in baseline non‐smokers, the relapse rate in baseline former smokers, and the abstinence rate in baseline current smokers were calculated, respectively. The associations between screening results, demographic characteristics, and smoking behavior change were analyzed using multivariable logistic regression. Results: From 2014 to 2019, smoking prevalence significantly decreased from 52.6% to 49.1%. The prevalence of smoking initiation, relapse, and abstinence in baseline non‐smokers, former, and current smokers was 16.8%, 22.9%, and 23.7%, respectively. The risk of smoking initiation in baseline non‐smokers was significantly higher in those with negative screening result (adjusted OR = 2.97, 95% CI: 1.27–6.94). Compared to smokers who only received baseline screening, the chance of smoking abstinence in baseline current smokers was reduced by over 80% in those who attended 5 rounds of screening (adjusted OR = 0.15, 95% CI:0.08–0.27). No significant associations were found between smoking relapse and prior screening frequency, with at least one positive screening result. Age, gender, occupational exposure, income, and smoking pack years were also associated with smoking behavior changes. Conclusions: The overall decreased smoking prevalence indicated an overwhelming effect of "teachable moment" on "license to smoke." A tailored smoking cessation strategy should be integrated into lung cancer screening. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results